Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.55 |
| ▸ | PARP1 | P09874 | 2/20 | 0.46 |
| ▸ | IGF1R | P08069 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4907440 | 0.94 | KDM1A (0.53) | KDM1APARP1IGF1R | |
| SCHEMBL4916171 | 0.94 | KDM1A (0.47) | KDM1APARP1IGF1RALDH1A1MAPT | |
| SCHEMBL4904595 | 0.94 | KDM1A (0.48) | KDM1APARP1IGF1RMEN1ALDH1A1 | |
| SCHEMBL4904556 | 0.93 | IGF1R (0.48) | KDM1AIGF1RMEN1ALDH1A1MAPT | |
| SCHEMBL4909277 | 0.91 | IDO1 (0.44) | KDM1APARP1IGF1RMEN1ALDH1A1 | |
| SCHEMBL4910913 | 0.91 | KDM1A (0.51) | KDM1APARP1IGF1RMEN1ALDH1A1 | |
| SCHEMBL4913007 | 0.89 | KDM1A (0.52) | KDM1APARP1IGF1R | |
| SCHEMBL4910324 | 0.89 | KDM1A (0.55) | KDM1APARP1IGF1R | |
| SCHEMBL4908994 | 0.89 | KDM1A (0.55) | KDM1APARP1IGF1RMEN1MAPT | |
| SCHEMBL4913437 | 0.89 | KDM1A (0.55) | KDM1APARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222297-B2 | e.g. 1-[3-(acridin-9-ylamino)-5-hydroxymethylphenyl]-3-{4-[bis(2-chloroethyl)amino]phenyl}urea; anticarcinogenic agent; improved chemical stability and efficacy; brain tumor, breast cancer, colon cancer, leukemia, and neuroblastoma | ACADEMIA SINICA (TW) | 2012-07-17 | — | — | US | disclosed |
| US-20080171765-A1 | Aniline or phenol mustards linked to DNA-affinic molecules or water-soluble aromatic rings and their use as cancer therapeutic agents | ACADEMIA SINICA (TW) | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171765-A1 | Aniline or phenol mustards linked to DNA-affinic molecules or water-soluble aromatic rings and their use as cancer therapeutic agents | WEE1, PCNA, ATIC | KDM1A 722/4885PARP1 778/4885IGF1R 3991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.